SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
36:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
and paclitaxel. Bevacizumab was admin-:@0.084848:0.096166:0.475719:0.096166:0.475719:0.080410:0.084848:0.080410:0.013143:0.011738:0.013181:0.006254:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.006254:0.011045:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.006254:0.015990:0.013143:0.007466:0.006254:0.013143:0.013181:0.018049:0.003848:0.011738:0.006388
istered  every  three  weeks  with  chemo-:@0.084848:0.112517:0.475765:0.112517:0.475765:0.096761:0.084848:0.096761:0.003848:0.007466:0.006523:0.012508:0.005715:0.012508:0.013181:0.005330:0.006358:0.012508:0.010660:0.012508:0.005792:0.010314:0.005330:0.006358:0.006523:0.011738:0.005707:0.012508:0.012508:0.005330:0.006354:0.015990:0.012508:0.012508:0.009660:0.007466:0.005330:0.006358:0.015990:0.003848:0.006523:0.011738:0.005330:0.006358:0.012450:0.011738:0.012508:0.018049:0.012604:0.006388
therapy and subsequently without for one :@0.084848:0.128868:0.481101:0.128868:0.481101:0.113112:0.084848:0.113112:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005503:0.013143:0.011738:0.013181:0.005503:0.007466:0.011699:0.013123:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.005503:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.005490:0.006042:0.012604:0.005792:0.005492:0.012604:0.011738:0.012508:0.005330
year until progression of disease. There :@0.084848:0.145219:0.481073:0.145219:0.481073:0.129463:0.084848:0.129463:0.010314:0.012508:0.013143:0.005792:0.012200:0.011699:0.011738:0.006523:0.003848:0.003848:0.012200:0.013123:0.005715:0.012604:0.012950:0.005711:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.012200:0.012604:0.006042:0.012200:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.012200:0.008197:0.011738:0.012508:0.005703:0.012508:0.005330
was  a  significant increase  in  median  sur-:@0.084848:0.161571:0.475756:0.161571:0.475756:0.145815:0.084848:0.145815:0.015990:0.013143:0.007466:0.005330:0.002894:0.013143:0.005330:0.002890:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.008213:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.005330:0.002890:0.003848:0.011738:0.005330:0.002890:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.005330:0.002890:0.007466:0.011699:0.005792:0.006388
vival from 10.3 months to 12.3 months. A :@0.084848:0.177922:0.481080:0.177922:0.481080:0.162166:0.084848:0.162166:0.010660:0.003848:0.010660:0.013143:0.003848:0.008120:0.006042:0.005711:0.012604:0.018049:0.008109:0.010660:0.010660:0.005330:0.010660:0.008120:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.008105:0.006523:0.012604:0.008105:0.010660:0.010660:0.005330:0.010660:0.008120:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.008101:0.014239:0.005330
marginal increase in progression-free sur-:@0.084848:0.194273:0.475739:0.194273:0.475739:0.178517:0.084848:0.178517:0.018049:0.013143:0.005809:0.012950:0.003848:0.011738:0.013143:0.003848:0.008293:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.008293:0.003848:0.011738:0.008293:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005709:0.012508:0.012508:0.008293:0.007466:0.011699:0.005792:0.006388
vival has been  reported  when  bevaci-:@0.084848:0.210624:0.475748:0.210624:0.475748:0.194868:0.084848:0.194868:0.010660:0.003848:0.010660:0.013143:0.003848:0.012103:0.011738:0.013143:0.007466:0.012103:0.013123:0.012508:0.012508:0.011738:0.005330:0.006762:0.005713:0.012508:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.005330:0.006752:0.015990:0.011738:0.012508:0.011738:0.005330:0.006760:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.006388
zumab  is administered  with cisplatin and :@0.084848:0.226976:0.481084:0.226976:0.481084:0.211220:0.084848:0.211220:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330:0.002973:0.003848:0.007466:0.008313:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005711:0.012508:0.013181:0.005330:0.002973:0.015990:0.003848:0.006523:0.011738:0.008313:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.008313:0.013143:0.011738:0.013181:0.005330
gemcitabine.:@0.084848:0.243327:0.210867:0.243327:0.210867:0.227571:0.084848:0.227571:0.012950:0.012508:0.018049:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330
18:@0.210864:0.237758:0.223294:0.237758:0.223294:0.228572:0.210864:0.228572:0.006215:0.006215
FIRST-LINE THERAPY  :@0.084848:0.276414:0.290934:0.276414:0.290934:0.258599:0.084848:0.258599:0.010263:0.005987:0.012401:0.011118:0.008980:0.008980:0.009407:0.005987:0.015822:0.011118:0.005987:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256:0.005965:0.005987
WITH BIOLOGICAL AGENTS:@0.084848:0.294244:0.355952:0.294244:0.355952:0.276429:0.084848:0.276429:0.019242:0.005987:0.008980:0.014539:0.005987:0.012401:0.005987:0.017960:0.009407:0.017960:0.017960:0.005987:0.016677:0.015822:0.009407:0.005987:0.015822:0.017960:0.011118:0.015822:0.008980:0.011118
PD1 and PDL1 inhibitors:@0.084848:0.312074:0.322599:0.312074:0.322599:0.294053:0.084848:0.294053:0.011973:0.014966:0.011973:0.005987:0.014111:0.012828:0.014111:0.005987:0.011973:0.014966:0.009407:0.011973:0.005987:0.005131:0.012828:0.012828:0.005131:0.014111:0.005131:0.006414:0.013683:0.006842:0.009407
Pembrolizimab and nivolumab are exam-:@0.084848:0.329571:0.475754:0.329571:0.475754:0.313815:0.084848:0.313815:0.011199:0.012315:0.017857:0.012931:0.005521:0.012411:0.003656:0.003656:0.007986:0.003656:0.017857:0.012950:0.012931:0.008043:0.012950:0.011545:0.012989:0.008043:0.011545:0.003656:0.010468:0.012411:0.003656:0.011507:0.017857:0.012950:0.012931:0.008043:0.012950:0.005521:0.012315:0.008043:0.012315:0.009044:0.012950:0.017857:0.006388
ples  of  these  drugs.  They  can  be  consid-:@0.084848:0.345922:0.475769:0.345922:0.475769:0.330166:0.084848:0.330166:0.012931:0.003656:0.012315:0.007274:0.005330:0.003375:0.012411:0.005850:0.005330:0.003375:0.006331:0.011545:0.012315:0.007274:0.012315:0.005330:0.003373:0.012989:0.005600:0.011507:0.012758:0.007274:0.005138:0.005330:0.003373:0.008005:0.011545:0.012315:0.010122:0.005330:0.003375:0.012257:0.012950:0.011545:0.005330:0.003375:0.012931:0.012315:0.005330:0.003375:0.012257:0.012411:0.011545:0.007274:0.003656:0.012989:0.006388
ered for tumours that do not have any of :@0.084848:0.362274:0.481123:0.362274:0.481123:0.346518:0.084848:0.346518:0.012315:0.005521:0.012315:0.012989:0.007283:0.005850:0.012411:0.005600:0.007283:0.006331:0.011507:0.017857:0.012411:0.011507:0.005600:0.007274:0.007283:0.006331:0.011545:0.012950:0.006331:0.007283:0.012989:0.012411:0.007283:0.011545:0.012411:0.006331:0.007283:0.011545:0.012950:0.010468:0.012315:0.007283:0.012950:0.011545:0.010122:0.007283:0.012411:0.006040:0.005330
the mutations mentioned previously. These :@0.084848:0.378625:0.481082:0.378625:0.481082:0.362869:0.084848:0.362869:0.006331:0.011545:0.012315:0.005811:0.017857:0.011507:0.006331:0.012950:0.006331:0.003656:0.012411:0.011545:0.007274:0.005811:0.017857:0.012315:0.011545:0.006331:0.003656:0.012411:0.011545:0.012315:0.012989:0.005811:0.012931:0.005519:0.012315:0.010468:0.003656:0.012411:0.011507:0.007274:0.003656:0.010122:0.005138:0.005811:0.008005:0.011545:0.012315:0.007274:0.012506:0.005330
drugs are active in the first-line setting in tu-:@0.084848:0.394976:0.475775:0.394976:0.475775:0.379220:0.084848:0.379220:0.012989:0.005600:0.011507:0.012758:0.007274:0.005157:0.012950:0.005521:0.012315:0.005157:0.012950:0.012257:0.006331:0.003656:0.010468:0.012315:0.005157:0.003656:0.011545:0.005157:0.006331:0.011545:0.012315:0.005157:0.004589:0.004589:0.005600:0.007274:0.006331:0.006196:0.003656:0.003656:0.011545:0.012315:0.005157:0.007274:0.012315:0.006331:0.006331:0.003656:0.011545:0.012758:0.005157:0.003656:0.011545:0.005157:0.006331:0.011507:0.006388
mours which express PDL1. Preliminary data :@0.084848:0.411327:0.481067:0.411327:0.481067:0.395571:0.084848:0.395571:0.017857:0.012411:0.011507:0.005600:0.007274:0.004330:0.015798:0.011545:0.003656:0.012257:0.011545:0.004330:0.012315:0.009044:0.012931:0.005521:0.012315:0.007274:0.007274:0.004330:0.011199:0.014124:0.008698:0.010468:0.005138:0.004330:0.011199:0.005521:0.012315:0.003656:0.003656:0.017857:0.003656:0.011545:0.012950:0.005600:0.010122:0.004330:0.012989:0.012950:0.006331:0.013144:0.005330
show an increase in progression-free surviv-:@0.084848:0.427679:0.475787:0.427679:0.475787:0.411923:0.084848:0.411923:0.007274:0.011545:0.012411:0.015798:0.005042:0.012950:0.011545:0.005042:0.003656:0.011545:0.012257:0.005521:0.012315:0.012950:0.007274:0.012315:0.005042:0.003656:0.011545:0.005042:0.012931:0.005521:0.012411:0.012758:0.005521:0.012315:0.007274:0.007274:0.003656:0.012411:0.011545:0.006196:0.005850:0.005519:0.012315:0.012315:0.005042:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.006388
al and overall survival, when compared to :@0.084848:0.444030:0.481082:0.444030:0.481082:0.428274:0.084848:0.428274:0.012950:0.003656:0.005946:0.012950:0.011545:0.012989:0.005946:0.012411:0.010468:0.012315:0.005600:0.012950:0.003656:0.003656:0.005946:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.005138:0.005946:0.015798:0.011545:0.012315:0.011545:0.005946:0.012257:0.012411:0.017857:0.012931:0.012950:0.005521:0.012315:0.012989:0.005946:0.006331:0.012600:0.005330
standard  chemotherapy.:@0.084848:0.460381:0.326214:0.460381:0.326214:0.444625:0.084848:0.444625:0.007274:0.006331:0.012950:0.011545:0.012989:0.012950:0.005482:0.012989:0.005330:0.010016:0.012257:0.011545:0.012315:0.017857:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005330
19 :@0.326009:0.454807:0.341322:0.454807:0.341322:0.445621:0.326009:0.445621:0.006103:0.006103:0.003107
Immune-relat-:@0.347165:0.460426:0.475760:0.460426:0.475760:0.444670:0.347165:0.444670:0.004156:0.017857:0.017857:0.011507:0.011545:0.012315:0.006196:0.005521:0.012315:0.003656:0.012950:0.006331:0.006388
ed side effects are the common toxicities. :@0.084853:0.476777:0.481142:0.476777:0.481142:0.461021:0.084853:0.461021:0.012315:0.012989:0.006600:0.007274:0.003656:0.012989:0.012315:0.006600:0.012315:0.005905:0.005850:0.012315:0.012257:0.006331:0.007274:0.006600:0.012950:0.005521:0.012315:0.006600:0.006331:0.011545:0.012315:0.006600:0.012257:0.012411:0.017857:0.017857:0.012411:0.011545:0.006600:0.006331:0.012411:0.009044:0.003656:0.012257:0.003656:0.006331:0.003656:0.012315:0.007274:0.005326:0.005330
These can occur after cessation of therapy. :@0.084853:0.493128:0.481110:0.493128:0.481110:0.477372:0.084853:0.477372:0.008005:0.011545:0.012315:0.007274:0.012315:0.004041:0.012257:0.012950:0.011545:0.004041:0.012411:0.012257:0.012257:0.011507:0.005600:0.004041:0.012950:0.005850:0.006331:0.012315:0.005600:0.004041:0.012257:0.012315:0.007274:0.007274:0.012950:0.006331:0.003656:0.012411:0.011545:0.004041:0.012411:0.005850:0.004041:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005328:0.005330
High-dose steroids may be required to con-:@0.084853:0.509479:0.475776:0.509479:0.475776:0.493723:0.084853:0.493723:0.012950:0.003656:0.012758:0.011545:0.006196:0.012989:0.012411:0.007274:0.012315:0.004464:0.007274:0.006331:0.012315:0.005521:0.012411:0.003656:0.012989:0.007274:0.004464:0.017857:0.012950:0.010122:0.004464:0.012931:0.012315:0.004464:0.005521:0.012315:0.012931:0.011507:0.003656:0.005521:0.012315:0.012989:0.004464:0.006331:0.012411:0.004464:0.012257:0.012411:0.011545:0.006388
trol these side effects. Immunosuppressive :@0.084853:0.525831:0.481100:0.525831:0.481100:0.510075:0.084853:0.510075:0.006331:0.005519:0.012411:0.003656:0.007658:0.006331:0.011545:0.012315:0.007274:0.012315:0.007649:0.007274:0.003656:0.012989:0.012315:0.007658:0.012315:0.005905:0.005850:0.012315:0.012257:0.006331:0.007274:0.005138:0.007649:0.004156:0.017857:0.017857:0.011507:0.011545:0.012411:0.007274:0.011507:0.012931:0.012931:0.005519:0.012315:0.007274:0.007274:0.003656:0.010468:0.012506:0.005330
therapy is an option in severe cases. Exam-:@0.084853:0.542182:0.475758:0.542182:0.475758:0.526426:0.084853:0.526426:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005061:0.003656:0.007274:0.005061:0.012950:0.011545:0.005061:0.012411:0.012931:0.006331:0.003656:0.012411:0.011545:0.005061:0.003656:0.011545:0.005061:0.007274:0.012315:0.010468:0.012315:0.005519:0.012315:0.005061:0.012257:0.012950:0.007274:0.012315:0.007274:0.005138:0.005061:0.010122:0.009044:0.012950:0.017857:0.006388
ples are cutaneous vitiligo, lichen planus, :@0.084853:0.558533:0.481106:0.558533:0.481106:0.542777:0.084853:0.542777:0.012931:0.003656:0.012315:0.007274:0.008794:0.012950:0.005521:0.012315:0.008794:0.012257:0.011507:0.006331:0.012950:0.011545:0.012315:0.012411:0.011507:0.007274:0.008794:0.010468:0.003656:0.006331:0.003656:0.003656:0.003656:0.012758:0.012411:0.005138:0.008794:0.003656:0.003656:0.012257:0.011545:0.012315:0.011545:0.008794:0.012931:0.003656:0.012950:0.011545:0.011507:0.007274:0.005326:0.005330
colitis, hepatitis and nephritis.:@0.084853:0.574884:0.349301:0.574884:0.349301:0.559128:0.084853:0.559128:0.012257:0.012411:0.003656:0.003656:0.006331:0.003656:0.007274:0.005138:0.005138:0.011545:0.012315:0.012931:0.012950:0.006331:0.003656:0.006331:0.003656:0.007274:0.005138:0.012950:0.011545:0.012989:0.005138:0.011545:0.012315:0.012931:0.011545:0.005600:0.003656:0.006331:0.003656:0.007274:0.005330
20:@0.349104:0.569305:0.361422:0.569305:0.361422:0.560119:0.349104:0.560119:0.006103:0.006215
SECOND-LINE THERAPY:@0.084848:0.607961:0.317895:0.607961:0.317895:0.590145:0.084848:0.590145:0.011118:0.011118:0.016677:0.017960:0.015822:0.014966:0.008980:0.009407:0.005987:0.015822:0.011118:0.005987:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
n   :@0.084848:0.622345:0.107657:0.622345:0.107657:0.613905:0.084848:0.613905:0.009762:0.003566:0.005914:0.003566
Docetaxel, has shown significantly :@0.104091:0.625464:0.426998:0.625464:0.426998:0.609708:0.104091:0.609708:0.014316:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.005330:0.011738:0.013143:0.007466:0.005330:0.007466:0.011738:0.012604:0.015990:0.011738:0.005330:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330
improved survival and QoL, when :@0.104091:0.641815:0.421171:0.641815:0.421171:0.626059:0.104091:0.626059:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.005330:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.013143:0.011738:0.013181:0.005330:0.016760:0.012604:0.008890:0.005330:0.005330:0.015990:0.011738:0.012508:0.011738:0.005330
compared to best supportive care :@0.104091:0.658166:0.431404:0.658166:0.431404:0.642411:0.104091:0.642411:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.005330:0.006523:0.012604:0.005330:0.013123:0.012508:0.007466:0.006523:0.005330:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.003848:0.010660:0.012508:0.005330:0.012450:0.013143:0.005698:0.012508:0.005330
in patients who have failed first-line :@0.104091:0.674518:0.434964:0.674518:0.434964:0.658762:0.104091:0.658762:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.006042:0.013143:0.003848:0.003848:0.012508:0.013181:0.005330:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330
therapy.:@0.104091:0.690869:0.182561:0.690869:0.182561:0.675113:0.104091:0.675113:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
n   :@0.084848:0.704129:0.107657:0.704129:0.107657:0.695689:0.084848:0.695689:0.009762:0.003566:0.005914:0.003566
Pemetrexed has an antitumour activity :@0.104091:0.707248:0.471011:0.707248:0.471011:0.691492:0.104091:0.691492:0.011392:0.012508:0.018049:0.012508:0.006523:0.005702:0.012508:0.009236:0.012508:0.013181:0.005330:0.011738:0.013143:0.007466:0.005330:0.013143:0.011738:0.005330:0.013143:0.011738:0.006523:0.003848:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005330
similar to docetaxel as a second-:@0.104091:0.723599:0.411950:0.723599:0.411950:0.707843:0.104091:0.707843:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.005330:0.006523:0.012604:0.005330:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.013143:0.007466:0.005330:0.013143:0.005330:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388
line therapy. The response rates for :@0.104091:0.739951:0.431900:0.739951:0.431900:0.724195:0.104091:0.724195:0.003848:0.003848:0.011738:0.012508:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.008197:0.011738:0.012508:0.005330:0.005692:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.006042:0.012604:0.005792:0.005330
both agents are just under 10% and :@0.104091:0.756302:0.439873:0.756302:0.439873:0.740546:0.104091:0.740546:0.013123:0.012604:0.006523:0.011738:0.005330:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.013143:0.005698:0.012508:0.005330:0.003906:0.011699:0.007466:0.006523:0.005330:0.011699:0.011738:0.013181:0.012508:0.005792:0.005330:0.010660:0.010660:0.014913:0.005330:0.013143:0.011738:0.013181:0.005330
the median survival around eight :@0.104091:0.772653:0.416743:0.772653:0.416743:0.756897:0.104091:0.756897:0.006523:0.011738:0.012508:0.005330:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.005330:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.013143:0.005717:0.012604:0.011699:0.011738:0.013181:0.005330:0.012508:0.003848:0.012950:0.011738:0.006523:0.005330
months. Pemetrexed has less toxicity :@0.104091:0.789004:0.447271:0.789004:0.447271:0.773248:0.104091:0.773248:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.005330:0.011392:0.012508:0.018049:0.012508:0.006523:0.005688:0.012508:0.009236:0.012508:0.013181:0.005330:0.011738:0.013143:0.007466:0.005330:0.003848:0.012508:0.007466:0.007466:0.005330:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330
with lower rates of neutropaenia and :@0.104091:0.805356:0.455305:0.805356:0.455305:0.789600:0.104091:0.789600:0.015990:0.003848:0.006523:0.011738:0.005330:0.003848:0.012604:0.015990:0.012508:0.005792:0.005330:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.012604:0.006042:0.005330:0.011738:0.012508:0.011699:0.006523:0.005678:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.013143:0.011738:0.013181:0.005330
neutropaenic sepsis.:@0.104091:0.821707:0.294213:0.821707:0.294213:0.805951:0.104091:0.805951:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.012450:0.005330:0.007466:0.012508:0.013123:0.007466:0.003848:0.007466:0.005330
21:@0.294222:0.816127:0.306652:0.816127:0.306652:0.806941:0.294222:0.806941:0.006215:0.006215
n   :@0.084848:0.834984:0.107657:0.834984:0.107657:0.826543:0.084848:0.826543:0.009762:0.003566:0.005914:0.003566
Erlotinib has been evaluated as a :@0.104091:0.838103:0.420898:0.838103:0.420898:0.822347:0.104091:0.822347:0.010314:0.005792:0.003848:0.012604:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.011738:0.013143:0.007466:0.005330:0.013123:0.012508:0.012508:0.011738:0.005330:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.012508:0.013181:0.005330:0.013143:0.007466:0.005330:0.013143:0.005330
second-line therapy in patients who :@0.104091:0.854454:0.442949:0.854454:0.442949:0.838698:0.104091:0.838698:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330
had not undergone EGFR gene-:@0.104091:0.870805:0.403252:0.870805:0.403252:0.855049:0.104091:0.855049:0.011738:0.013143:0.013181:0.005330:0.011738:0.012604:0.006523:0.005330:0.011699:0.011738:0.013181:0.012508:0.005792:0.012950:0.012604:0.011738:0.012508:0.005330:0.010314:0.016779:0.009333:0.011680:0.005330:0.012950:0.012508:0.011738:0.012508:0.006388
mutation analysis. There was a :@0.104091:0.887156:0.391563:0.887156:0.391563:0.871400:0.104091:0.871400:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.013143:0.011738:0.013143:0.003848:0.010314:0.007466:0.003848:0.007466:0.005330:0.005330:0.008197:0.011738:0.012508:0.005705:0.012508:0.005330:0.015990:0.013143:0.007466:0.005330:0.013143:0.005330
statistical increase in response rates :@0.104091:0.903508:0.439047:0.903508:0.439047:0.887752:0.104091:0.887752:0.007466:0.006523:0.013143:0.006523:0.003848:0.007466:0.006523:0.003848:0.012450:0.013143:0.003848:0.005330:0.003848:0.011738:0.012450:0.005725:0.012508:0.013143:0.007466:0.012508:0.005330:0.003848:0.011738:0.005330:0.005709:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330
(9%:@0.104091:0.919859:0.136764:0.919859:0.136764:0.904103:0.104091:0.904103:0.007100:0.010660:0.014913
 versus:@0.136764:0.919859:0.197686:0.919859:0.197686:0.904103:0.136764:0.904103:0.005330:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 1%) and survival (6.7 months:@0.197686:0.919859:0.464058:0.919859:0.464058:0.904103:0.197686:0.904103:0.005330:0.010660:0.014913:0.007100:0.005330:0.013143:0.011738:0.013181:0.005330:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.007100:0.010660:0.005330:0.010660:0.005330:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466
 :@0.464058:0.919859:0.469389:0.919859:0.469389:0.904103:0.464058:0.904103:0.005330
versus:@0.104091:0.936210:0.159682:0.936210:0.159682:0.920454:0.104091:0.920454:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 4.7 months) in these patients. The :@0.159682:0.936210:0.477836:0.936210:0.477836:0.920454:0.159682:0.920454:0.005330:0.010660:0.005330:0.010660:0.005330:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.007100:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005330:0.008197:0.011738:0.012508:0.005330
importance of EGFR gene mutation has :@0.543491:0.096132:0.918179:0.096132:0.918179:0.080376:0.543491:0.080376:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.012450:0.012508:0.005330:0.012604:0.006042:0.005330:0.010314:0.016779:0.009333:0.011680:0.005330:0.012950:0.012508:0.011738:0.012508:0.005330:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.011738:0.013143:0.007466:0.005330
subsequently been recognised.:@0.543491:0.112562:0.836335:0.112562:0.836335:0.096806:0.543491:0.096806:0.007466:0.011699:0.013123:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.005330:0.013123:0.012508:0.012508:0.011738:0.005330:0.005709:0.012508:0.012450:0.012604:0.012950:0.011738:0.003848:0.007466:0.012508:0.013181:0.005330
22:@0.836320:0.106981:0.848750:0.106981:0.848750:0.097795:0.836320:0.097795:0.006215:0.006215
SMALL-CELL LUNG CARCINOMA:@0.524242:0.142180:0.882664:0.142180:0.882664:0.122584:0.524242:0.122584:0.012230:0.021167:0.017404:0.010348:0.010348:0.009878:0.018344:0.012230:0.010348:0.010348:0.006585:0.010348:0.015052:0.017404:0.019756:0.006585:0.018344:0.017404:0.013641:0.018344:0.006585:0.017404:0.019756:0.021167:0.017404
Small-cell lung  carcinoma  comprises :@0.524242:0.160907:0.920476:0.160907:0.920476:0.145151:0.524242:0.145151:0.009583:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.022263:0.003848:0.011699:0.011738:0.012950:0.005330:0.016920:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.016922:0.012450:0.012604:0.018049:0.013123:0.005792:0.003848:0.007466:0.012508:0.007466:0.005330
about 15% of all lung cancers. It is strongly :@0.524242:0.177338:0.920489:0.177338:0.920489:0.161582:0.524242:0.161582:0.013143:0.013123:0.012604:0.011699:0.006523:0.005451:0.010660:0.010660:0.014913:0.005465:0.012604:0.006042:0.005451:0.013143:0.003848:0.003848:0.005465:0.003848:0.011699:0.011738:0.012950:0.005451:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.005448:0.004349:0.006523:0.005455:0.003848:0.007466:0.005465:0.007466:0.006523:0.005713:0.012604:0.011738:0.012950:0.003848:0.010314:0.005330
related to smoking. It has neuro-endocrine :@0.524242:0.193769:0.920508:0.193769:0.920508:0.178013:0.524242:0.178013:0.005713:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.004503:0.006523:0.012604:0.004503:0.007466:0.018049:0.012604:0.009660:0.003848:0.011738:0.012950:0.005330:0.004503:0.004349:0.006523:0.004503:0.011738:0.013143:0.007466:0.004503:0.011738:0.012508:0.011699:0.005705:0.012604:0.006388:0.012508:0.011738:0.013181:0.012604:0.012450:0.005792:0.003848:0.011738:0.012508:0.005330
differentiation and is more commonly as-:@0.524242:0.210199:0.915155:0.210199:0.915155:0.194443:0.524242:0.194443:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.007222:0.013143:0.011738:0.013181:0.007235:0.003848:0.007466:0.007235:0.018049:0.012604:0.005707:0.012508:0.007235:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.003848:0.010314:0.007224:0.013143:0.007466:0.006388
sociated with paraneoplastic syndromes. :@0.524242:0.226630:0.920464:0.226630:0.920464:0.210874:0.524242:0.210874:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.008082:0.015990:0.003848:0.006523:0.011738:0.008082:0.013123:0.013143:0.005792:0.013143:0.011738:0.012508:0.012604:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.008082:0.007466:0.010314:0.011738:0.013181:0.005717:0.012604:0.018049:0.012508:0.007466:0.005330:0.005330
It is a rapidly growing tumour and metas-:@0.524242:0.243060:0.915167:0.243060:0.915167:0.227305:0.524242:0.227305:0.004349:0.006523:0.006860:0.003848:0.007466:0.006870:0.013143:0.006870:0.005792:0.013143:0.013123:0.003848:0.013181:0.003848:0.010314:0.006870:0.012950:0.005709:0.012604:0.015990:0.003848:0.011738:0.012950:0.006856:0.006523:0.011699:0.018049:0.012604:0.011699:0.005778:0.006870:0.013143:0.011738:0.013181:0.006870:0.018049:0.012508:0.006523:0.013143:0.007466:0.006388
tasises early. All patients are considered :@0.524242:0.259491:0.920497:0.259491:0.920497:0.243735:0.524242:0.243735:0.006523:0.013143:0.007466:0.003848:0.007466:0.012508:0.007466:0.009640:0.012508:0.013143:0.005792:0.003848:0.010314:0.005330:0.009640:0.014239:0.003848:0.003848:0.009640:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009640:0.013143:0.005715:0.012508:0.009640:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.005330
to have micro metastases. Untreated, the :@0.524242:0.275922:0.920476:0.275922:0.920476:0.260166:0.524242:0.260166:0.006523:0.012604:0.006081:0.011738:0.013143:0.010660:0.012508:0.006081:0.018049:0.003848:0.012450:0.005715:0.012604:0.006081:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.006081:0.012604:0.011738:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.006081:0.006523:0.011738:0.012508:0.005330
median survival of patients will be approxi-:@0.524242:0.292352:0.915153:0.292352:0.915153:0.276596:0.524242:0.276596:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.004580:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.004580:0.012604:0.006042:0.004566:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004580:0.015990:0.003848:0.003848:0.003848:0.004580:0.013123:0.012508:0.004570:0.013143:0.013123:0.013123:0.005721:0.012604:0.009236:0.003848:0.006388
mately three months. However, it is sensi-:@0.524242:0.308783:0.915155:0.308783:0.915155:0.293027:0.524242:0.293027:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.007755:0.006523:0.011738:0.005707:0.012508:0.012508:0.007743:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.007735:0.013143:0.012604:0.015990:0.012508:0.010660:0.012508:0.003766:0.005330:0.007745:0.003848:0.006523:0.007755:0.003848:0.007466:0.007755:0.007466:0.012508:0.011738:0.007466:0.003848:0.006388
tive to chemotherapy, which prolongs sur-:@0.524242:0.325214:0.915163:0.325214:0.915163:0.309458:0.524242:0.309458:0.006523:0.003848:0.010660:0.012508:0.005061:0.006523:0.012604:0.005051:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005043:0.015990:0.011738:0.003848:0.012450:0.011738:0.005061:0.013123:0.005715:0.012604:0.003848:0.012604:0.011738:0.012950:0.007466:0.005061:0.007466:0.011699:0.005792:0.006388
vival and improves patients’ performance :@0.524242:0.341644:0.920466:0.341644:0.920466:0.325888:0.524242:0.325888:0.010660:0.003848:0.010660:0.013143:0.003848:0.004986:0.013143:0.011738:0.013181:0.004965:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.007466:0.004965:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006754:0.004965:0.013123:0.012508:0.006708:0.006042:0.012604:0.006317:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330
status (PS). Patients are rarely cured.:@0.524242:0.358075:0.860903:0.358075:0.860903:0.342319:0.524242:0.342319:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330:0.007100:0.011392:0.009583:0.007100:0.005330:0.005330:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.013143:0.005703:0.012508:0.005330:0.005792:0.013143:0.005705:0.012508:0.003848:0.010314:0.005330:0.012450:0.011699:0.005713:0.012508:0.013181:0.005330
STAGING AND EVALUATION:@0.524242:0.391306:0.806036:0.391306:0.806036:0.373491:0.524242:0.373491:0.011118:0.008980:0.015822:0.017960:0.005987:0.015822:0.017960:0.005987:0.015822:0.015822:0.014966:0.005987:0.011118:0.014966:0.015822:0.009407:0.013683:0.015822:0.008980:0.005987:0.017960:0.015822
The 2016 TNM staging system is used. Pa-:@0.524242:0.408887:0.915163:0.408887:0.915163:0.393131:0.524242:0.393131:0.008197:0.011738:0.012508:0.007468:0.010660:0.010660:0.010672:0.010660:0.007485:0.008197:0.014239:0.017684:0.007466:0.007466:0.006523:0.013143:0.012950:0.003848:0.011738:0.012950:0.007476:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.007485:0.003848:0.007466:0.007485:0.011699:0.007466:0.012508:0.013181:0.005330:0.007474:0.011392:0.013143:0.006388
tients with SCLC can also be staged using :@0.524242:0.425317:0.920481:0.425317:0.920481:0.409561:0.524242:0.409561:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005850:0.015990:0.003848:0.006523:0.011738:0.005850:0.009583:0.015644:0.008890:0.015644:0.005850:0.012450:0.013143:0.011738:0.005850:0.013143:0.003848:0.007466:0.012604:0.005850:0.013123:0.012508:0.005850:0.007466:0.006523:0.013143:0.012950:0.012508:0.013181:0.005850:0.011699:0.007466:0.003848:0.011738:0.012950:0.005330
a binary staging system, i.e. as having lo-:@0.524242:0.441748:0.915169:0.441748:0.915169:0.425992:0.524242:0.425992:0.013143:0.007004:0.013123:0.003848:0.011738:0.013143:0.005792:0.010314:0.007004:0.007466:0.006523:0.013143:0.012950:0.003848:0.011738:0.012950:0.006995:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.005330:0.007004:0.003848:0.005330:0.012508:0.005330:0.006993:0.013143:0.007466:0.007004:0.011738:0.013143:0.010660:0.003848:0.011738:0.012950:0.007004:0.003848:0.012604:0.006388
calised or extensive disease (LD and ED). :@0.524242:0.458179:0.920470:0.458179:0.920470:0.442423:0.524242:0.442423:0.012450:0.013143:0.003848:0.003848:0.007466:0.012508:0.013181:0.007254:0.012604:0.005792:0.007243:0.012508:0.009236:0.006523:0.012508:0.011738:0.007466:0.003848:0.010660:0.012508:0.007254:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.007254:0.007100:0.008890:0.014316:0.007254:0.013143:0.011738:0.013181:0.007254:0.010314:0.014316:0.007100:0.005330:0.005330
LD can be treated within one radiation :@0.524242:0.474609:0.920458:0.474609:0.920458:0.458853:0.524242:0.458853:0.008890:0.014316:0.010045:0.012450:0.013143:0.011738:0.010045:0.013123:0.012508:0.010045:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.010045:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.010045:0.012604:0.011738:0.012508:0.010045:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
port. This includes the hemi-thorax and re-:@0.524242:0.491040:0.915165:0.491040:0.915165:0.475284:0.524242:0.475284:0.013123:0.012604:0.005792:0.006523:0.005330:0.005750:0.008197:0.011738:0.003848:0.007466:0.005773:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.005761:0.006523:0.011738:0.012508:0.005755:0.011738:0.012508:0.018049:0.003848:0.006388:0.006523:0.011738:0.012604:0.005792:0.013143:0.009236:0.005755:0.013143:0.011738:0.013181:0.005761:0.005713:0.012508:0.006388
gional nodes, as well as mediastinal and :@0.524242:0.507471:0.920493:0.507471:0.920493:0.491715:0.524242:0.491715:0.012950:0.003848:0.012604:0.011738:0.013143:0.003848:0.007859:0.011738:0.012604:0.013181:0.012508:0.007466:0.005330:0.007855:0.013143:0.007466:0.007870:0.015990:0.012508:0.003848:0.003848:0.007870:0.013143:0.007466:0.007870:0.018049:0.012508:0.013181:0.003848:0.013143:0.007466:0.006523:0.003848:0.011738:0.013143:0.003848:0.007870:0.013143:0.011738:0.013181:0.005330
ipsilateral supraclavicular nodes.:@0.524242:0.523901:0.826925:0.523901:0.826925:0.508145:0.524242:0.508145:0.003848:0.013123:0.007466:0.003848:0.003848:0.013143:0.006523:0.012508:0.005792:0.013143:0.003848:0.005330:0.007466:0.011699:0.013123:0.005792:0.013143:0.012450:0.003848:0.013143:0.010660:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.005330:0.011738:0.012604:0.013181:0.012508:0.007466:0.005330
Pre-treatment  evaluation includes a :@0.542426:0.540332:0.920476:0.540332:0.920476:0.524576:0.542426:0.524576:0.011392:0.005709:0.012508:0.006388:0.006523:0.005707:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012631:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.003848:0.012604:0.011738:0.017972:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.017972:0.013143:0.005330
complete blood-cell count;  liver-function :@0.524242:0.556762:0.920485:0.556762:0.920485:0.541006:0.524242:0.541006:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.008293:0.013123:0.003848:0.012604:0.012604:0.013181:0.006388:0.012450:0.012508:0.003848:0.003848:0.008293:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330:0.005330:0.002948:0.003848:0.003848:0.010660:0.012508:0.005792:0.006388:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
tests, CT of the chest and abdomen and a :@0.524242:0.573193:0.920491:0.573193:0.920491:0.557437:0.524242:0.557437:0.006523:0.012508:0.007466:0.006523:0.007466:0.005330:0.004695:0.015644:0.008197:0.004695:0.012604:0.006042:0.004695:0.006523:0.011738:0.012508:0.004695:0.012450:0.011738:0.012508:0.007466:0.006523:0.004695:0.013143:0.011738:0.013181:0.004695:0.013143:0.013123:0.013181:0.012604:0.018049:0.012508:0.011738:0.004686:0.013143:0.011738:0.013181:0.004695:0.013143:0.005330
bone scan. PET-CT scans may have a role :@0.524242:0.589624:0.920491:0.589624:0.920491:0.573868:0.524242:0.573868:0.013123:0.012604:0.011738:0.012508:0.005857:0.007466:0.012450:0.013143:0.011738:0.005330:0.005869:0.011392:0.010314:0.008197:0.006388:0.015644:0.008197:0.005854:0.007466:0.012450:0.013143:0.011738:0.007466:0.005869:0.018049:0.013143:0.010314:0.005869:0.011738:0.013143:0.010660:0.012508:0.005869:0.013143:0.005869:0.005713:0.012604:0.003848:0.012508:0.005330
in evaluating patients with limited disease.:@0.524242:0.606054:0.915132:0.606054:0.915132:0.590298:0.524242:0.590298:0.003848:0.011738:0.005003:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.003848:0.011738:0.012950:0.005003:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005003:0.015990:0.003848:0.006523:0.011738:0.005003:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005003:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
CHEMOTHERAPY:@0.524242:0.639286:0.691865:0.639286:0.691865:0.621470:0.524242:0.621470:0.016677:0.014539:0.011118:0.019242:0.017960:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
All patients  with SCLC may  be  consid-:@0.524242:0.656866:0.915161:0.656866:0.915161:0.641110:0.524242:0.641110:0.014624:0.004233:0.004233:0.009987:0.013508:0.013527:0.006908:0.004233:0.012892:0.012123:0.006908:0.007851:0.005330:0.004647:0.016375:0.004233:0.006908:0.012123:0.009987:0.009968:0.016029:0.009275:0.016029:0.009987:0.018434:0.013527:0.010699:0.005330:0.004647:0.013508:0.012892:0.005330:0.004647:0.012835:0.012989:0.012123:0.007851:0.004233:0.013566:0.006388
ered for chemotherapy,  irrespective of :@0.524242:0.673297:0.920516:0.673297:0.920516:0.657541:0.524242:0.657541:0.012892:0.006098:0.012892:0.013566:0.009621:0.006427:0.012989:0.006177:0.009621:0.012835:0.012123:0.012892:0.018434:0.012989:0.006908:0.012123:0.012892:0.006177:0.013527:0.013508:0.010699:0.005715:0.005330:0.004291:0.004233:0.006177:0.006098:0.012892:0.007851:0.013508:0.012892:0.012835:0.006908:0.004233:0.011045:0.012892:0.009621:0.012989:0.006042:0.005330
PS,  unlike patients with NSCLC where :@0.524242:0.689728:0.920497:0.689728:0.920497:0.673972:0.524242:0.673972:0.011776:0.009968:0.005715:0.005330:0.007524:0.012084:0.012123:0.004233:0.004233:0.010045:0.012892:0.012873:0.013508:0.013527:0.006908:0.004233:0.012892:0.012123:0.006908:0.007851:0.012873:0.016375:0.004233:0.006908:0.012123:0.012873:0.014624:0.009968:0.016029:0.009275:0.016029:0.012873:0.016375:0.012123:0.012892:0.006098:0.012506:0.005330
chemotherapy  is  restricted  to  patients :@0.524242:0.706158:0.920501:0.706158:0.920501:0.690402:0.524242:0.690402:0.012835:0.012123:0.012892:0.018434:0.012989:0.006908:0.012123:0.012892:0.006177:0.013527:0.013508:0.010699:0.005330:0.006148:0.004233:0.007851:0.005330:0.006148:0.006096:0.012892:0.007851:0.006908:0.006177:0.004233:0.012835:0.006908:0.012892:0.013566:0.005330:0.006148:0.006908:0.012989:0.005330:0.006148:0.013508:0.013527:0.006908:0.004233:0.012892:0.012123:0.006908:0.007470:0.005330
with good PS.:@0.524242:0.722589:0.655263:0.722589:0.655263:0.706833:0.524242:0.706833:0.016375:0.004233:0.006908:0.012123:0.005715:0.013335:0.012989:0.012989:0.013566:0.005715:0.011776:0.009968:0.005330
A platinum combined with etoposide :@0.542426:0.739019:0.920501:0.739019:0.920501:0.723263:0.542426:0.723263:0.014239:0.011642:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.011642:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.012508:0.013181:0.011642:0.015990:0.003848:0.006523:0.011738:0.011642:0.012508:0.006523:0.012604:0.013123:0.012604:0.007466:0.003848:0.013181:0.012508:0.005330
is  most frequently used nowadays. Cispl-:@0.524242:0.755450:0.915151:0.755450:0.915151:0.739694:0.524242:0.739694:0.003848:0.007466:0.005330:0.003244:0.018049:0.012604:0.007466:0.006523:0.008563:0.006042:0.005713:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.008563:0.011699:0.007466:0.012508:0.013181:0.008563:0.011738:0.012604:0.015990:0.013143:0.013181:0.013143:0.010314:0.007466:0.005330:0.008563:0.015644:0.003848:0.007466:0.013123:0.003877:0.006388
atin is the platinum of choice in patients :@0.524242:0.771881:0.920478:0.771881:0.920478:0.756125:0.524242:0.756125:0.013143:0.006523:0.003848:0.011738:0.008130:0.003848:0.007466:0.008140:0.006523:0.011738:0.012508:0.008122:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.008128:0.012604:0.006042:0.008124:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.008122:0.003848:0.011738:0.008130:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with LD who  are candidates for  concur-:@0.524242:0.788311:0.915151:0.788311:0.915151:0.772555:0.524242:0.772555:0.015990:0.003848:0.006523:0.011738:0.008871:0.008890:0.014316:0.008871:0.015990:0.011738:0.012604:0.005330:0.003529:0.013143:0.005713:0.012508:0.008871:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.008871:0.006042:0.012604:0.005792:0.005330:0.003525:0.012450:0.012604:0.011738:0.012450:0.011699:0.005763:0.006388
rent chemotherapy and irradiation to the :@0.524242:0.804742:0.920497:0.804742:0.920497:0.788986:0.524242:0.788986:0.005713:0.012508:0.011738:0.006523:0.006504:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012490:0.005792:0.013143:0.013123:0.010314:0.006523:0.013143:0.011738:0.013181:0.006512:0.003848:0.005792:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.006510:0.006523:0.012604:0.006506:0.006523:0.011738:0.012508:0.005330
chest. Patients who cannot tolerate  a :@0.524242:0.821173:0.920499:0.821173:0.920499:0.805417:0.524242:0.805417:0.012450:0.011738:0.012508:0.007466:0.006523:0.005330:0.013335:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.013335:0.015990:0.011738:0.012604:0.013335:0.012450:0.013143:0.011738:0.011738:0.012604:0.006514:0.013335:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.005330:0.007993:0.013143:0.005330
platinum agent may be treated with the :@0.524242:0.837603:0.920456:0.837603:0.920456:0.821847:0.524242:0.821847:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.007658:0.013143:0.012950:0.012508:0.011738:0.006523:0.007658:0.018049:0.013143:0.010314:0.007658:0.013123:0.012508:0.007658:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.007658:0.015990:0.003848:0.006523:0.011738:0.007658:0.006523:0.011738:0.012508:0.005330
CAV regimen (cyclophosphamide, doxo-:@0.524242:0.854034:0.915157:0.854034:0.915157:0.838278:0.524242:0.838278:0.015644:0.011886:0.013508:0.007986:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007970:0.007100:0.012450:0.010314:0.012450:0.003848:0.012604:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.013143:0.018049:0.003848:0.013181:0.012508:0.005330:0.007976:0.013181:0.012604:0.009236:0.012604:0.006388
rubicin, vincristine). This regimen was previ-:@0.524242:0.870464:0.915128:0.870464:0.915128:0.854708:0.524242:0.854708:0.005792:0.011699:0.013123:0.003848:0.012450:0.003848:0.011738:0.005330:0.004560:0.010660:0.003848:0.011738:0.012450:0.005792:0.003848:0.007466:0.006523:0.003848:0.011738:0.012508:0.007100:0.005330:0.004560:0.008197:0.011738:0.003848:0.007466:0.004560:0.005711:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.004560:0.015990:0.013143:0.007466:0.004560:0.013123:0.005715:0.012508:0.010660:0.003848:0.006388
ously used as standard therapy.:@0.524242:0.886895:0.819482:0.886895:0.819482:0.871139:0.524242:0.871139:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330:0.011699:0.007466:0.012508:0.013181:0.005330:0.013143:0.007466:0.005330:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005680:0.013181:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
Patients receive between four to six cy-:@0.542426:0.903326:0.915178:0.903326:0.915178:0.887570:0.542426:0.887570:0.011199:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.007649:0.005521:0.012315:0.012257:0.012315:0.003656:0.010468:0.012315:0.007649:0.012931:0.012315:0.006331:0.015798:0.012315:0.012315:0.011545:0.007649:0.005850:0.012411:0.011507:0.005600:0.007649:0.006331:0.012411:0.007649:0.007274:0.003656:0.009044:0.007658:0.012257:0.010122:0.006388
cles of treatment. There is no gain in increas-:@0.524242:0.919756:0.915170:0.919756:0.915170:0.904000:0.524242:0.904000:0.012257:0.003656:0.012315:0.007274:0.003492:0.012411:0.005850:0.003491:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.005138:0.003492:0.008005:0.011545:0.012315:0.005519:0.012315:0.003491:0.003656:0.007274:0.003492:0.011545:0.012411:0.003491:0.012758:0.012950:0.003656:0.011545:0.003491:0.003656:0.011545:0.003491:0.003656:0.011545:0.012257:0.005521:0.012315:0.012950:0.007274:0.006388
ing the dose intensity of chemotherapy :@0.524242:0.936187:0.920524:0.936187:0.920524:0.920431:0.524242:0.920431:0.003656:0.011545:0.012758:0.011680:0.006331:0.011545:0.012315:0.011680:0.012989:0.012411:0.007274:0.012315:0.011680:0.003656:0.011545:0.006331:0.012315:0.011545:0.007274:0.003656:0.006331:0.010122:0.011680:0.012411:0.005850:0.011680:0.012257:0.011545:0.012315:0.017857:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010318:0.005330